Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30430615 | 1.00 | GPR3 (0.41) | GPR3LMNATP53MEN1KMT2A | |
| SCHEMBL18805435 | 0.75 | CYP2A6 (0.35) | GPR3LMNATP53MEN1KMT2A | |
| SCHEMBL13178097 | 0.74 | LMNA (0.33) | LMNATSHRALOX12ACHE | |
| SCHEMBL23030081 | 0.74 | CA1 (0.37) | CA9CA2CA12CA1 | |
| SCHEMBL23030082 | 0.74 | CA1 (0.35) | CA9CA2CA12CA1 | |
| SCHEMBL8024079 | 0.73 | GPR3 (0.41) | GPR3LMNATP53MEN1KMT2A | |
| SCHEMBL11638030 | 0.73 | GPR3 (0.41) | GPR3LMNATP53MEN1KMT2A | |
| SCHEMBL4466424 | 0.73 | LMNA (0.32) | LMNATSHRALOX12ACHE | |
| SCHEMBL10860629 | 0.73 | GPR3 (0.41) | GPR3LMNATP53MEN1KMT2A | |
| SCHEMBL11633944 | 0.73 | GPR3 (0.41) | GPR3LMNATP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4602081-A1 | PHOTO-SWITCHABLE CHEMISTRY FOR REVERSIBLE HYDROGELS AND REUSABLE FLOW CELLS | Illumina, Inc. (US) | 2025-08-20 | — | — | EP | claimed |
| WO-2024081563-A1 | PHOTO-SWITCHABLE CHEMISTRY FOR REVERSIBLE HYDROGELS AND REUSABLE FLOW CELLS | ILLUMINA, INC. (US) | 2024-04-18 | — | — | WO | claimed |
| EP-2970107-B1 | PHOTOSWITCHABLE HDAC INHIBITORS | MASSACHUSETTS GEN HOSPITAL (US) | 2023-11-15 | — | — | EP | claimed |
| EP-3068405-B1 | PYRROLO [1,2,F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2019-05-01 | — | — | EP | claimed |
| EP-3323414-A1 | INHIBITORS OF NEDD8-ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2018-05-23 | — | — | EP | claimed |
| US-9890178-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-13 | — | — | US | claimed |
| EP-3177299-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | Alios Biopharma, Inc. (US) | 2017-06-14 | — | — | EP | claimed |
| US-9493469-B2 | Piperidine inhibitors of Janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | claimed |
| US-20160237096-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-18 | — | — | US | claimed |
| US-9321767-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-26 | — | — | US | claimed |
| US-7015305-B2 | Process for preparing glycopeptide derivatives | THERAVANCE, INC. (US) | 2006-03-21 | — | — | US | claimed |
| US-6979723-B2 | Process for preparing glycopeptide phosphonate derivatives | THERAVANCE, INC. (US) | 2005-12-27 | — | — | US | claimed |
| EP-1419174-A4 | PROCESS FOR PREPARING GLYCOPEPTIDE DERIVATIVES | THERAVANCE INC (US) | 2005-10-12 | — | — | EP | claimed |
| EP-1418933-A4 | PROCESS FOR PREPARING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE INC (US) | 2004-10-27 | — | — | EP | claimed |
| EP-1418933-A2 | PROCESS FOR PREPARING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | Theravance, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| EP-1419174-A2 | PROCESS FOR PREPARING GLYCOPEPTIDE DERIVATIVES | Theravance, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| WO-2003029270-A2 | PROCESS FOR PREPARING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2003-04-10 | — | — | WO | claimed |
| US-20030069391-A1 | Process for preparing glycopeptide phosphonate derivatives | CUMBERLAND PHARMACEUTICALS INC. | 2003-04-10 | — | — | US | claimed |
| US-20030045457-A1 | Process for preparing glycopeptide derivatives | CUMBERLAND PHARMACEUTICALS INC. | 2003-03-06 | — | — | US | claimed |
| WO-2003018607-A2 | PROCESS FOR PREPARING GLYCOPEPTIDE DERIVATIVES | THERAVANCE, INC. (US) | 2003-03-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045457-A1 | Process for preparing glycopeptide derivatives | GYPA, VIP, OGT | GPR3 2290/4885LMNA 2789/4885TP53 3209/4885 |
| US-20160237096-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | AZI2, ZC3HAV1, ZC3HAV1L | GPR3 4514/4885LMNA 3136/4885TP53 2157/4885 |
| US-20030069391-A1 | Process for preparing glycopeptide phosphonate derivatives | PGLS, GYPA, PAG1 | GPR3 2622/4885LMNA 2995/4885TP53 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.